|Slideshows|May 28, 2020

Dosing Secrets for the Top Mood Stabilizers

These mood stabilizers cover a lot of ground, but it is important to know how to use them.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Categories vs Dimensions: Wave or Particle?

ByS. Nassir Ghaemi, MD, MPH,Mark L. Ruffalo, MSW, DPsa

July 29th 2026

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

ByAshley A. Mulvihill, MD ,Susan Hatters Friedman, MD, MSt, DFAPA

July 17th 2026

Brain Trust: Addiction Pharmacotherapy in Bipolar Disorder, Rethinking Comorbidity With Michael J. Ostacher, MD, MPH

ByJoseph F. Goldberg, MD,Michael J. Ostacher, MD, MPH

July 1st 2026

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

ByJoseph F. Goldberg, MD,David Dunner, MD, FACPsych

June 26th 2026

Keeping Up To Date With Bipolar Disorder

ByMichael E. Henry, MD

June 15th 2026

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Dosing Secrets for the Top Mood Stabilizers

Related Content

Categories vs Dimensions: Wave or Particle?

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

Brain Trust: Addiction Pharmacotherapy in Bipolar Disorder, Rethinking Comorbidity With Michael J. Ostacher, MD, MPH

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

Keeping Up To Date With Bipolar Disorder

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD